19982-38-8

Usage

InChI:InChI=1/C10H10N2O2S/c1-2-13-8-6-4-3-5-7(8)9-11-12-10(15)14-9/h3-6H,2H2,1H3,(H,12,15)

Upstream product

• 463-71-8 thiophosgene 
• 21018-13-3 2-ethoxybenzoic acid hydrazide 
• 19982-41-3 N'-(2-ethoxy-benzoyl)-hydrazinecarbodithioic acid; potassium salt 
• 75-15-0 carbon disulfide 
• 3686-55-3 methyl 2-ethoxybenzoate 
• 134-11-2 2-ethoxybenzoic acid 
• 6290-24-0 ethyl 2-ethoxybenzoate 

Downstream Products

• 19982-30-0 [5-(2-ethoxy-phenyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-acetic acid ethyl ester 
• 1257842-79-7 2-chloro-5-[[(5-(o-ethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio]methyl]pyridine 
• 838586-63-3 2-(benzylthio)-5-(2-ethoxyphenyl)-1,3,4-oxadiazole 
• 838814-08-7 2-(5-(2-ethoxyphenyl)-1,3,4-oxadiazol-2-ylthio)-1-phenylethanone 
• 1260218-06-1 2-(2-Ethoxyphenyl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole 
• 19982-34-4 5-(2-ethoxy-phenyl)-3H-[1,3,4]oxadiazol-2-one 
• 19982-27-5 5-[5-(2-ethoxy-phenyl)-[1,3,4]oxadiazol-2-ylsulfanylmethyl]-3H-[1,3,4]oxadiazol-2-one 
• 19982-31-1 3-acetyl-5-(2-ethoxy-phenyl)-3H-[1,3,4]oxadiazol-2-one 
• 19982-33-3 2-ethanesulfonyl-5-(2-ethoxy-phenyl)-[1,3,4]oxadiazole 
• 19982-28-6 [5-(2-ethoxy-phenyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-acetic acid hydrazide 
• 19982-29-7 [5-(2-ethoxy-phenyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-acetic acid 

Relevant academic research and scientific papers

Ultrasound-assisted, one-pot, three-component synthesis and antibacterial activities of novel indole derivatives containing 1,3,4-oxadiazole and 1,2,4-triazole moieties

Thirteen novel indole derivatives were efficiently synthesized through ultrasound irradiation by using 4-amino-5-(1H-indol-3-yl)-4H-[1,2,4]triazole-3-thiol (8) and 2-mercapto-5-substituted-1,3,4-oxadiazoles (5a-m). Compared with conventional and microwave methods, yields increased to 82-93%, and reaction times decreased to 15-35 min. The structures of these novel compounds were characterized by spectral data and elemental analysis. Two out of the synthesized compounds (10f and 10l) exhibited excellent activity against Staphylococcus aureus and Escherichia coli, and thus warrant further research.

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.

Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives

In present study, a series of new 2-(1,3,4-oxadiazol-2-ylthio)-1- phenylethanone derivatives (6a-6x) as potential focal adhesion kinase (FAK) inhibitors were synthesized. The bioassay assays demonstrated that compound 6i showed the most potent activity, which inhibited the growth of MCF-7 and A431 cell lines with IC50 values of 140 ± 10 nM and 10 ± 1 nM, respectively. Compound 6i also exhibited significant FAK inhibitory activity (IC50 = 20 ± 1 nM). Docking simulation was performed to position compound 6i into the active site of FAK to determine the probable binding model.

Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents

A series of 2-(benzylthio)-5-aryloxadiazole derivatives have been designed and synthesized, and their biological activities are also evaluated for EGFR inhibitory activity. Fourteen compounds among the twenty compounds are reported for the first time. Their chemical structures are characterized by 1H NMR, MS, and elemental analysis. Anti-proliferative and EGFR inhibition assay results have demonstrated that compound 3e shows the most potent biological activity (IC50 = 1.09 μM for MCF-7 and IC50 = 1.51 μM for EGFR). Docking simulation has been performed to position compound 3e into the EGFR active site to determine the probable binding model, with an estimated binding free energy value of -10.7 kcal/mol. Compound 3e with potent inhibitory activity in tumor growth inhibition may be a promising anti-tumor leading compound for the further research.

Synthesis, biological evaluation, and molecular docking studies of 2-chloropyridine derivatives possessing 1,3,4-oxadiazole moiety as potential antitumor agents

A series of new 2-chloropyridine derivatives possessing 1,3,4-oxadiazole moiety were synthesized. Antiproliferative assay results indicated that compounds 6o and 6u exhibited the most potent activity against gastric cancer cell SGC-7901, which was more potent than the positive control. Especially, compound 6o exhibited significant telomerase inhibitory activity (IC 50 = 2.3 ± 0.07 μM), which was comparable to the positive control ethidium bromide. Docking simulation was performed to position compound 6o into the active site of telomerase (3DU6) to determine the probable binding model.

COMPOUNDS AND METHODS FOR TREATING LEUKEMIA

Compounds hat are inhibitors of transcription factors of leukemia cell lines are provided. In addition, pharmaceutical compositions including the inhibiting compounds and methods for treating leukemia are also provided.